NEWS RELEASE

The settlement agreement permits Par to begin selling a generic version of Suboxone® film on January 1, 2023, or earlier under certain circumstances. Par is IntelGenx’s commercial and development partner for a generic version of Suboxone® sublingual film product, which is indicated for the treatment of opioid dependence.

“We are very pleased with this outcome,” commented Dr. Horst G. Zerbe, President and CEO of IntelGenx. “According to IMS data, the oral film market for opioid dependence in the United States was worth more than $1.8 billion in 2017.  That is undoubtedly larger today as the opioid abuse epidemic has continued to grow.”

About Opioid Addiction

Opioid addiction is one of the fastest growing public health epidemics in North America. In the U.S. alone, 2.5 million people struggle with opioid addiction and, according to the U.S. Centers for Disease Control, 78 people die each day from the disease. The Drug Addiction Treatment Act of 2000 allowed medical office-based treatment of opioid dependence and greatly expanded patient access to medication-assisted treatments. In 2015, the U.S. Health and Human Services Department announced it would move to expand access to medication-assisted-treatment even further by revising regulations that cap the number of patients who can be treated with buprenorphine products by physicians.

About Suboxone®

The U.S. Food and Drug Administration approved Suboxone® film in October of 2002 for use in the treatment of opioid dependence.  Suboxone® is a registered trademark of Indivior UK Limited and Suboxone® film is manufactured by Aquestive Therapeutics, Inc. Suboxone® film is composed of the two active ingredients: buprenorphine hydrochloride and naloxone hydrochloride.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
This email address is being protected from spambots. You need JavaScript enabled to view it.

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
This email address is being protected from spambots. You need JavaScript enabled to view it.